home / stock / pptdf / pptdf quote
Last: | $9.50 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $9.50 |
High: | $0 |
Low: | $0 |
Volume: | 2 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.5 | $0 | $9.5 | $0 | $0 | 2 | 04-03-2024 |
$9.5 | $9.5 | $9.5 | $9.5 | $9.5 | 205 | 03-22-2024 |
$9.5 | $9.5 | $9.5 | $9.5 | $9.5 | 600 | 03-07-2024 |
$8.56 | $0 | $8.56 | $0 | $0 | 80 | 02-20-2024 |
$8.56 | $8.56 | $8.56 | $8.56 | $8.56 | 100 | 02-14-2024 |
$8.56 | $8.56 | $8.56 | $8.56 | $8.56 | 136 | 12-01-2023 |
$8.32 | $8.32 | $8.32 | $8.32 | $8.32 | 200 | 11-30-2023 |
$7.4 | $0 | $7.4 | $0 | $0 | 2,300 | 11-14-2023 |
$7.4 | $0 | $7.4 | $0 | $0 | 2 | 11-10-2023 |
$7.4 | $7.4 | $7.4 | $7.4 | $7.4 | 700 | 10-31-2023 |
$7.45 | $7.45 | $7.45 | $7.45 | $7.45 | 300 | 10-27-2023 |
$8.2 | $8.21 | $8.2 | $8.21 | $8.2 | 200 | 10-26-2023 |
$9.924 | $9.924 | $9.924 | $9.924 | $9.924 | 600 | 10-06-2023 |
$11.6 | $0 | $11.6 | $0 | $0 | 1 | 09-25-2023 |
$11.6 | $0 | $11.6 | $0 | $0 | 1 | 09-21-2023 |
$11.6 | $11.6 | $11.6 | $11.6 | $11.6 | 418 | 09-14-2023 |
$12.402 | $0 | $12.402 | $0 | $0 | 2,310 | 08-25-2023 |
$12.402 | $12.402 | $12.402 | $12.402 | $12.402 | 180 | 08-02-2023 |
$13.605 | $13.605 | $13.605 | $13.605 | $13.605 | 100 | 03-28-2023 |
$13.4 | $13.4 | $13.4 | $13.4 | $13.4 | 100 | 03-14-2023 |
News, Short Squeeze, Breakout and More Instantly...
PeptiDream Inc Company Name:
PPTDF Stock Symbol:
OTCMKTS Market:
NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific mo...
NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific mol...
NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, today announced the presentation of proof-of-concept data on KPMW101, an anti-tum...